Mandate

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

June 19, 2024

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.

ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.

The Vinge team primarily consisted of Johan Larsson, Maria Dahlin Kolvik, Stojan Arnerstål, David Olander, Johan Gavelin, Olof Löfvenberg and Alice Göransson.

Related

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026

Vinge advises Stendörren in connection with issuance of green capital securities

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026